- Home
- STAI vs SYBX Comparison
STAI vs SYBX Comparison
Compare STAI & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STAI
- SYBX
- Stock Information
- Founded
- STAI 2011
- SYBX N/A
- Country
- STAI United States
- SYBX United States
- Employees
- STAI N/A
- SYBX N/A
- Industry
- STAI
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- STAI
- SYBX Health Care
- Exchange
- STAI Nasdaq
- SYBX Nasdaq
- Market Cap
- STAI 16.6M
- SYBX 13.6M
- IPO Year
- STAI N/A
- SYBX N/A
- Fundamental
- Price
- STAI $0.68
- SYBX $1.20
- Analyst Decision
- STAI
- SYBX
- Analyst Count
- STAI 0
- SYBX 0
- Target Price
- STAI N/A
- SYBX N/A
- AVG Volume (30 Days)
- STAI 485.0K
- SYBX 6.1K
- Earning Date
- STAI 01-01-0001
- SYBX 08-07-2025
- Dividend Yield
- STAI N/A
- SYBX N/A
- EPS Growth
- STAI N/A
- SYBX N/A
- EPS
- STAI N/A
- SYBX 0.21
- Revenue
- STAI $542,166.00
- SYBX N/A
- Revenue This Year
- STAI N/A
- SYBX N/A
- Revenue Next Year
- STAI N/A
- SYBX N/A
- P/E Ratio
- STAI N/A
- SYBX $5.78
- Revenue Growth
- STAI N/A
- SYBX N/A
- 52 Week Low
- STAI $0.62
- SYBX $0.90
- 52 Week High
- STAI $9.07
- SYBX $1.88
- Technical
- Relative Strength Index (RSI)
- STAI N/A
- SYBX 54.75
- Support Level
- STAI N/A
- SYBX $1.18
- Resistance Level
- STAI N/A
- SYBX $1.27
- Average True Range (ATR)
- STAI 0.00
- SYBX 0.05
- MACD
- STAI 0.00
- SYBX -0.00
- Stochastic Oscillator
- STAI 0.00
- SYBX 58.33
About STAI ScanTech AI Systems Inc. Common stock
ScanTech AI Systems Inc is developing and deploying security screening systems that protect travelers and other public members from criminals, terrorists, and other bad actors. It has developed a proprietary Computed Tomography scanning system that uses fixed-gantry technology to detect explosives, weapons, narcotics, and other contraband.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.